Recombinant Adeno-Associated Virus (rAAV) has established itself as the leading vector for in vivo gene therapy. However, commercial-scale rAAV production faces significant biomanufacturing challenges. Traditional triple plasmid transient transfection relies on high quantities of costly GMP-grade helper and rep/cap plasmids, suffers from lot-to-lot batch variability, and often yields a high proportion of empty viral capsids that increase host immunogenicity risks.
To solve these bioprocess bottlenecks, Protheragen presents the large-scale dual-plasmid aav production platform. By consolidating helper genes (E2A, E4, VA RNA) and Rep/Cap genes into a single engineered helper/packaging plasmid, paired with the Transgene Transfer plasmid, our proprietary dual plasmid system combined with high-density HEK293 suspension cell culture dramatically simplifies biomanufacturing. This breakthrough lowers raw material expenditures, increases full-capsid packaging efficiency, and provides a seamless, scalable path from preclinical research to cGMP clinical manufacturing.
Fig.1 Triple plasmid system vs. dual plasmid system. (van Lieshout, Laura P, et al., 2023)
Engineered Dual-Plasmid Architecture
High-Density HEK293 Suspension Bioprocessing
Serum-free, chemically defined suspension culture technology adapted for automated stirred-tank bioreactor systems (scalable from 2L up to 500L+).
Advanced Downstream Purification & Quality Control
Integrated tangential flow filtration (TFF), affinity chromatography, and iodixanol/CsCl ultracentrifugation or anion-exchange chromatography (AEX) to achieve ultra-high vector purity (>95%) and strict control over empty-to-full capsid ratios.
| Manufacturing Metric | Conventional 3-Plasmid System | Protheragen Dual-Plasmid System |
| Number of Plasmid Inputs | 3 (Transfer, Rep/Cap, Ad-Helper) | 2 (Transfer + Integrated Rep/Cap/Helper) |
| Plasmid Raw Material Cost | High (Requires 3 GMP plasmid batches) | Significantly Reduced (~30–40% cost reduction) |
| Transfection Stoichiometry | Complex 3-way ratio balancing; higher batch variation | Simplified 2-way ratio; superior batch-to-batch repeatability. |
| Full Capsid Yield (%) | Variable (typically 20%–50% prior to enrichment) | Consistently High (up to 70%+ full capsids pre-AEX) |
| Scalability (Bioreactor Volumes) | Adhesion or complex suspension scaling. | Seamless scalability in serum-free suspension (up to 500L+). |
| Residual Host DNA & Impurities | Higher risk due to excess plasmid mass. | Markedly reduced residual host/plasmid DNA background. |
Protheragen offers tailored CRO/CDMO solutions to optimize ocular target delivery for your gene therapy candidates:
Dual-Plasmid Vector Design & Construct Optimization
Re-engineering standard 3-plasmid constructs into optimized 2-plasmid configurations for custom AAV serotypes and novel capsids.
Preclinical Research Grade (RUO) Packaging
Flexible small-to-mid scale production (100 mL to 10L) for candidate screening, cell assays, and animal model evaluations.
High-Titer Bioreactor Scale-Up Process Development
Process parameters optimization (MOI, transfection reagents, feed strategy) in 2L, 10L, 50L, to 200L+ automated suspension bioreactors.
Downstream Purification & Empty/Full Capsid Enrichment
Customized AEX and affinity chromatography workflows tailored to maximize full-capsid ratios and remove residual host protein/DNA.
Comprehensive Analytical QC & Release Testing
Full analytical panel including ddPCR/qPCR (viral genome titer), AUC/TEM (full/empty ratio analysis), SDS-PAGE/HPLC (capsid purity), and endotoxin/bioburden safety testing.
cGMP-Ready Process Transfer & CMC Documentation Support
Complete process development reports, regulatory dossier support (IND/CTA filings), and seamless transfer to cGMP manufacturing suites.
Our Dual-Plasmid Large-Scale Production Platform meets the high-volume vector supply demands across diverse gene therapy fields:
At Protheragen, we bridge the gap between innovative viral vector engineering and scalable biomanufacturing. By combining our proprietary Dual plasmid technology with advanced HEK293 suspension bioprocessing, we provide a reliable, cost-effective, and cGMP-ready manufacturing route for your AAV pipeline. Partner with Protheragen to lower your vector production costs, accelerate process development, and secure high-purity AAV supplies from preclinical proof-of-concept to clinical trials.
Talk to our AAV bioprocessing and CMC scientists today to discuss your production scale, request a dual-plasmid feasibility trial, or get a custom manufacturing quote.
Reference
Our AAVLinkTM platform is at the forefront of adeno-associated viral (AAV) vector development, leveraging our extensive expertise and state-of-the-art technologies to drive innovation in gene therapy.
